Antibody Discovery Market - Focus on Services and Platforms: Industry Trends and Global Forecasts, till 2035 - Distribution by Antibody Discovery Step, Antibody Discovery Method, Nature of, Type of Antibody, Therapeutic Area, End-user and Geographical Reg
Description
Antibody Discovery Market: Overview
As per Roots Analysis, the antibody discovery market is estimated to grow from USD 2.4 billion in the current year to USD 6.6 billion by 2035, representing a higher CAGR of 10.5% during the forecast period.
The market sizing and opportunity analysis has been segmented across the following parameters:
Antibody Discovery Step
Antibodies play a pivotal role in the identification and neutralization of foreign substances. Owing to several beneficial features, such as high specificity, and a favorable safety profile, these molecules have emerged as a promising alternative, particularly for the treatment of cancer, autoimmune diseases, and infectious diseases. It is worth highlighting that, at present, antibodies represent the largest class of biologics, with over 80 molecules approved till date and over 200 molecules in the preclinical / discovery stages.
Despite multiple approvals, various challenges in the domain remain unaddressed across several stages of design, production, and clinical application. Therefore, given the complexities of modern drug development, several companies prefer to outsource as a strategic solution to optimize their research efforts. This expected shift can be attributed to various reasons, such as reduced timelines, lessened financial risks associated with failed trials and accelerated workflows. At present, around 125 players are offering a wide array of antibody discovery services.
This field possesses significant promise for future breakthroughs, wherein advances in artificial intelligence and machine learning is expected to be crucial, facilitating the prediction of antibody-antigen interactions and enhancing the efficiency of lead identification.
Fueled by these developments, the antibody discovery market is expected to progress in the coming years, benefiting multiple stakeholders who have consistently fostered innovation in this field
Antibody discovery market: Key Insights
The report delves into the current state of the antibody discovery market and identifies potential growth opportunities within industry. Some key findings from the report include:
Lead Optimization Segment Captures that Majority of the Market Share
Based on the antibody discovery step, the services segment of antibody discovery market is distributed across lead optimization, lead selection and hit generation. Currently, the lead optimization sub-segment occupies the majority (61%) of the share in the overall market. It is worth highlighting that lead optimization ensures the selection of high-quality antibody candidates in terms of affinity, stability, and specificity, thereby increasing their likelihood of clinical success.
Antibody Discovery Services Segment is leading the Antibody Discovery Market
Based on the discovery method, the services segment of antibody discovery market is segmented into hybridoma-based methods, phage display library-based methods, transgenic animal-based methods, yeast display-based methods, single cell-based methods and other methods.
Presently, the market is dominated by hybridoma-based methods (35%) since the popularity of hybridoma-based methods for the discovery of antibodies has risen, owing to its efficiency and low complexity. Moreover, hybridoma-based methods have been crucial in developing therapeutic monoclonal antibodies used in treatment of diseases, including cancer, autoimmune disorders, and infections.
Based on Nature of Antibody, Human Antibodies Sub-Segment Occupies the Highest Share
Based on the nature of antibody, the services segment of antibody discovery market is segmented into human antibodies, humanized antibodies, chimeric antibodies and murine antibodies. The human antibodies sub-segment occupies the highest share (53%) in the current global services market. Several benefits associated with human antibodies, including reduced immunogenicity and the increased serum half-life of the monoclonal antibodies in humans, contribute to the high market share.
Oncological Disorders Dominate the Current Antibody Discovery Market
The global market value for services segment of antibody discovery market, based on different therapeutic areas, is segmented into oncological disorders, immunological disorders, infectious diseases, cardiovascular disorders, neurological disorders and other disorders. Currently, the market is dominated by oncological disorders sub-segment (48%). This can be attributed to the fact that incidence of oncological disorders has been on the rise globally, necessitating the development and production of effective treatments, including antibody-based therapeutics.
By Type of Antibody, Monoclonal Antibodies are Likely to Dominate the Market During the Forecast Period
Based on the type of antibody, the global services segment of antibody discovery market is segmented into monoclonal antibodies, bispecific antibodies and immunoconjugates. In the current year, the market is dominated by monoclonal antibodies (60%) and the trend is unlikely to change in the future as well. This can be attributed to the fact that monoclonal antibodies offer high specificity, consistency, and reproducibility, which makes them ideal for targeted therapies. In addition, mAbs have proven to be highly effective in treating a range of diseases, including cancer, autoimmune disorders, and infectious diseases.
Similarly, based on the type of antibody, the global technologies / platforms market is segmented into monoclonal antibodies, bispecific antibodies, antibody drug conjugates and other antibodies.
The Technologies / Platforms Market is the Fastest Growing Segment of the During the Forecast Period
In terms of end-user, the global technologies / platforms market segment of antibody discovery market is segmented across different end-users, namely in-house players and contract research organizations. In-house players’ sub-segment (98%) occupies the highest market share. This can be attributed to the fact that in-house players mostly have dedicated teams, access to extensive in-house resources, and control over intellectual property, which enables them to streamline the discovery process and maintain competitive advantages.
North America Accounts for the Largest Share of the Market
This segment highlights the distribution of global services market size across geographical regions, such as North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America. Our estimates suggest that the majority share in the current year is captured by North America (50%) owing to the presence of big pharma players, well-established regulatory framework, and various technological advancements in this region. On the contrary, Asia-Pacific is poised for the healthy growth rate (with a CAGR of 13.3%) during the forecast period.
Likewise, technologies / platforms market is segmented across various geographies, including North America, Europe and Asia-Pacific. Our estimates suggest that, North America is likely to capture the majority of the overall market share driven by maximum number of technology licensing / integration deals inked by technology / platform providers headquartered in this region.
Further, the market in Asia-Pacific is anticipated to increase at a faster pace (CAGR of 9.30%) in the foreseen future.
Primary Research Overview
The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in the market. In addition, the research report features detailed transcripts of interviews held with the industry stakeholders (arranged in decreasing order of seniority level):
As per Roots Analysis, the antibody discovery market is estimated to grow from USD 2.4 billion in the current year to USD 6.6 billion by 2035, representing a higher CAGR of 10.5% during the forecast period.
The market sizing and opportunity analysis has been segmented across the following parameters:
Antibody Discovery Step
- Hit Generation
- Lead Selection
- Lead Optimization
- Hybridoma-based Methods
- Phage Display Library-based Methods
- Transgenic Animal-based Methods
- Yeast Display-based Methods
- Single Cell-based Methods
- Other Methods
- Human Antibodies
- Humanized Antibodies
- Chimeric Antibodies
- Murine Antibodies
- Oncological Disorders
- Immunological Disorders
- Infectious Diseases
- Cardiovascular Disorders
- Neurological Disorders
- Other Disorders
- Monoclonal Antibodies
- Bispecific Antibodies
- Antibody Drug Conjugates
- Immunoconjugates
- Other Antibodies
- In-house Players
- Contract Research Organizations
- North America
- Europe
- Asia Pacific
- Middle East and North Africa
- Latin America
Antibodies play a pivotal role in the identification and neutralization of foreign substances. Owing to several beneficial features, such as high specificity, and a favorable safety profile, these molecules have emerged as a promising alternative, particularly for the treatment of cancer, autoimmune diseases, and infectious diseases. It is worth highlighting that, at present, antibodies represent the largest class of biologics, with over 80 molecules approved till date and over 200 molecules in the preclinical / discovery stages.
Despite multiple approvals, various challenges in the domain remain unaddressed across several stages of design, production, and clinical application. Therefore, given the complexities of modern drug development, several companies prefer to outsource as a strategic solution to optimize their research efforts. This expected shift can be attributed to various reasons, such as reduced timelines, lessened financial risks associated with failed trials and accelerated workflows. At present, around 125 players are offering a wide array of antibody discovery services.
This field possesses significant promise for future breakthroughs, wherein advances in artificial intelligence and machine learning is expected to be crucial, facilitating the prediction of antibody-antigen interactions and enhancing the efficiency of lead identification.
Fueled by these developments, the antibody discovery market is expected to progress in the coming years, benefiting multiple stakeholders who have consistently fostered innovation in this field
Antibody discovery market: Key Insights
The report delves into the current state of the antibody discovery market and identifies potential growth opportunities within industry. Some key findings from the report include:
- Presently, close to 125 players across the globe claim to offer customized services in order to support the operations related to antibody discovery; majority of these firms are based in North America.
- A relatively large proportion (88%) of the service providers offer hit generation services; of these, 57% employ library-based methods in order to support the discovery of antibodies for different therapeutic purposes.
- Close to 265 antibody discovery technologies are currently available in the market; these have revolutionized the field of antibody discovery by accelerating the identification and development of highly specific antibodies.
- Nearly 60% of the technologies employ library-based methods for antibody discovery; of these, 45% of the technologies support the discovery of monoclonal antibodies.
- Stakeholders are actively enhancing their existing capabilities and strengthening their competencies in order to gain an edge in the antibody discovery services domain.
- In pursuit of gaining a competitive edge, industry stakeholders are actively innovating and developing novel antibody discovery technologies / platforms that can support the discovery of multiple type of antibodies.
- 60% of the partnership deals have been inked post-2021; technology / product licensing agreements have emerged as the most prominent types of partnership models
- Foreseeing lucrative returns, many public and private investors have made investments worth USD 36 billion since 2020; of this, 70% of the total amount was raised by players based in North America.
- Given the rising demand for targeted biologics and personalized medicine, the antibody discovery market is anticipated to grow at an annualized rate (CAGR) of 10.1% till 2035
- The market opportunity for service providers using hybridoma-based methods is likely to be the highest; in terms of type of antibody, monoclonal antibodies sub-segment is anticipated to grow substantially.
- In the long term, the antibody discovery platforms for monoclonal antibodies are likely to emerge as the key contributor; Asia-Pacific is anticipated to be the fastest growing region.
Lead Optimization Segment Captures that Majority of the Market Share
Based on the antibody discovery step, the services segment of antibody discovery market is distributed across lead optimization, lead selection and hit generation. Currently, the lead optimization sub-segment occupies the majority (61%) of the share in the overall market. It is worth highlighting that lead optimization ensures the selection of high-quality antibody candidates in terms of affinity, stability, and specificity, thereby increasing their likelihood of clinical success.
Antibody Discovery Services Segment is leading the Antibody Discovery Market
Based on the discovery method, the services segment of antibody discovery market is segmented into hybridoma-based methods, phage display library-based methods, transgenic animal-based methods, yeast display-based methods, single cell-based methods and other methods.
Presently, the market is dominated by hybridoma-based methods (35%) since the popularity of hybridoma-based methods for the discovery of antibodies has risen, owing to its efficiency and low complexity. Moreover, hybridoma-based methods have been crucial in developing therapeutic monoclonal antibodies used in treatment of diseases, including cancer, autoimmune disorders, and infections.
Based on Nature of Antibody, Human Antibodies Sub-Segment Occupies the Highest Share
Based on the nature of antibody, the services segment of antibody discovery market is segmented into human antibodies, humanized antibodies, chimeric antibodies and murine antibodies. The human antibodies sub-segment occupies the highest share (53%) in the current global services market. Several benefits associated with human antibodies, including reduced immunogenicity and the increased serum half-life of the monoclonal antibodies in humans, contribute to the high market share.
Oncological Disorders Dominate the Current Antibody Discovery Market
The global market value for services segment of antibody discovery market, based on different therapeutic areas, is segmented into oncological disorders, immunological disorders, infectious diseases, cardiovascular disorders, neurological disorders and other disorders. Currently, the market is dominated by oncological disorders sub-segment (48%). This can be attributed to the fact that incidence of oncological disorders has been on the rise globally, necessitating the development and production of effective treatments, including antibody-based therapeutics.
By Type of Antibody, Monoclonal Antibodies are Likely to Dominate the Market During the Forecast Period
Based on the type of antibody, the global services segment of antibody discovery market is segmented into monoclonal antibodies, bispecific antibodies and immunoconjugates. In the current year, the market is dominated by monoclonal antibodies (60%) and the trend is unlikely to change in the future as well. This can be attributed to the fact that monoclonal antibodies offer high specificity, consistency, and reproducibility, which makes them ideal for targeted therapies. In addition, mAbs have proven to be highly effective in treating a range of diseases, including cancer, autoimmune disorders, and infectious diseases.
Similarly, based on the type of antibody, the global technologies / platforms market is segmented into monoclonal antibodies, bispecific antibodies, antibody drug conjugates and other antibodies.
The Technologies / Platforms Market is the Fastest Growing Segment of the During the Forecast Period
In terms of end-user, the global technologies / platforms market segment of antibody discovery market is segmented across different end-users, namely in-house players and contract research organizations. In-house players’ sub-segment (98%) occupies the highest market share. This can be attributed to the fact that in-house players mostly have dedicated teams, access to extensive in-house resources, and control over intellectual property, which enables them to streamline the discovery process and maintain competitive advantages.
North America Accounts for the Largest Share of the Market
This segment highlights the distribution of global services market size across geographical regions, such as North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America. Our estimates suggest that the majority share in the current year is captured by North America (50%) owing to the presence of big pharma players, well-established regulatory framework, and various technological advancements in this region. On the contrary, Asia-Pacific is poised for the healthy growth rate (with a CAGR of 13.3%) during the forecast period.
Likewise, technologies / platforms market is segmented across various geographies, including North America, Europe and Asia-Pacific. Our estimates suggest that, North America is likely to capture the majority of the overall market share driven by maximum number of technology licensing / integration deals inked by technology / platform providers headquartered in this region.
Further, the market in Asia-Pacific is anticipated to increase at a faster pace (CAGR of 9.30%) in the foreseen future.
Primary Research Overview
The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in the market. In addition, the research report features detailed transcripts of interviews held with the industry stakeholders (arranged in decreasing order of seniority level):
- Chief Executive Officer and Chief Scientific Officer, Small Company, US
- Chief Executive Officer and General Manager, Small Company, Germany
- Chief Executive Officer, Small Company, US
- Former Chief Executive Officer, Large Company, US
- Chief Business Officer, Mid-sized Company, US
- Chief Business Officer, Mid-sized Company, US
- Former Chief Business Officer, Small Company, US
- Former Chief Scientific Officer, Large Company, US
- President and Chief Operating Officer, Small Company, US
- Founder and Chief Technology Officer, Small Company, US
- Founder and President, Small Company, US
- Vice President of Commercial Services, Mid-sized Company, US
- Senior Vice President, Small Company, US
- Co-founder and Director of Emerging Science and Technology, Large Company, Canada
- Co-founder and Director, Small Company, India
- Former Site Director, Large Company, US
- Business Development Manager, Small Company, US
- Ablexis
- Abwiz Bio
- Abzena
- Aragen Life Sciences
- BIOTEM
- ChemPartner
- Creative Biolabs
- DetaiBio
- FairJourney Biologics
- Fusion Antibodies
- Genmab
- Harbour BioMed
- Immunome
- ImmunoPrecise Antibodies
- Integral Molecular
- Isogenica
- ProteoGenix
- Syd Labs
- Viva Biotech
- WuXi Biologics
- Antibody Discovery Services Market Sizing and Opportunity Analysis: The report features a thorough analysis of the global antibody discovery market, in terms of the key market segments, namely [A] antibody discovery step [B] type of antibody discovery method, [C] and nature of antibody [D] therapeutic area [E] type of antibody and [F] geographical regions.
- Antibody Discovery Technologies / Platforms Market: The report features a thorough analysis of the global antibody discovery market, in terms of the key market segments, namely [A] type of antibody [B] type of end-user, [C] and geographical regions.
- Market Landscape: An in-depth assessment of the companies involved in antibody discovery market, based on several relevant parameters, such as [A] year of establishment, [B] company size, [C] location of headquarters, [D] type of antibody discovery service offered, [E] type of antibody discovery supported, [F] type of antibody discovery method, [G] animal model used, [H] application area.
- Company Competitiveness Analysis: A comprehensive competitive analysis of antibody contract manufacturers, examining factors, such as [A] developer strength and [B] portfolio strength and [C] portfolio diversity.
- Technology Competitiveness Analysis: A comprehensive competitive analysis of antibody discovery technologies / platforms, examining factors, such as [A] developer strength and [B] portfolio strength and [C] portfolio diversity.
- Company Profiles: Detailed profiles of key developers engaged in the antibody discovery market, focused on [A] overview of the company, [B] financial information (if available), [C] antibody discovery service portfolio, and [D] recent developments and an informed future outlook.
- Partnerships and Collaborations: An insightful analysis of the various partnerships and collaborations signed in the antibody discovery market, based on various parameters, such as [A] year of partnership [B] type of partnership [C] type of antibody and [D] geography.
- Funding and Investment Analysis: An insightful analysis of the overall funding and investments reported in this domain, based on various parameters, such as [A] year of funding [B] type of funding and [C] geography.
- How many companies are currently engaged in this market?
- Which are the leading companies in this market?
- What factors are likely to influence the evolution of this market?
- What is the current and future market size?
- What is the CAGR of this market?
- How is the current and future market opportunity likely to be distributed across key market segments?
- The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
- Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
- The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.
- Complimentary Excel Data Packs for all Analytical Modules in the Report
- 15% Free Content Customization
- Detailed Report Walkthrough Session with Research Team
- Free Updated report if the report is 6-12 months old or older
Table of Contents
607 Pages
- Section I: Report Overview
- 1. Preface
- 1.1. Introduction
- 1.2. Market Share Insights
- 1.3. Key Market Insights
- 1.4. Report Coverage
- 1.5. Key Questions Answered
- 1.6. Chapter Outlines
- 2. Research Methodology
- 2.1. Chapter Overview
- 2.2. Research Assumptions
- 2.2.1. Market Landscape And Market Trends
- 2.2.2. Market Forecast And Opportunity Analysis
- 2.2.3. Comparative Analysis
- 2.3. Database Building
- 2.3.1. Data Collection
- 2.3.2. Data Validation
- 2.3.3. Data Analysis
- 2.4. Project Methodology
- 2.4.1. Secondary Research
- 2.4.1.1. Annual Reports
- 2.4.1.2. Academic Research Papers
- 2.4.1.3. Company Websites
- 2.4.1.4. Investor Presentations
- 2.4.1.5. Regulatory Filings
- 2.4.1.6. White Papers
- 2.4.1.7. Industry Publications
- 2.4.1.8. Conferences And Seminars
- 2.4.1.9. Government Portals
- 2.4.1.10. Media And Press Releases
- 2.4.1.11. Newsletters
- 2.4.1.12. Industry Databases
- 2.4.1.13. Roots Proprietary Databases
- 2.4.1.14. Paid Databases And Sources
- 2.4.1.15. Social Media Portals
- 2.4.1.16. Other Secondary Sources
- 2.4.2. Primary Research
- 2.4.2.1. Types Of Primary Research
- 2.4.2.1.1. Qualitative Research
- 2.4.2.1.2. Quantitative Research
- 2.4.2.1.3. Hybrid Approach
- 2.4.2.2. Advantages Of Primary Research
- 2.4.2.3. Techniques For Primary Research
- 2.4.2.3.1. Interviews
- 2.4.2.3.2. Surveys
- 2.4.2.3.3. Focus Groups
- 2.4.2.3.4. Observational Research
- 2.4.2.3.5. Social Media Interactions
- 2.4.2.4. Key Opinion Leaders Considered In Primary Research
- 2.4.2.4.1. Company Executives (Cxos)
- 2.4.2.4.2. Board Of Directors
- 2.4.2.4.3. Company Presidents And Vice Presidents
- 2.4.2.4.4. Research And Development Heads
- 2.4.2.4.5. Technical Experts
- 2.4.2.4.6. Subject Matter Experts
- 2.4.2.4.7. Scientists
- 2.4.2.4.8. Doctors And Other Healthcare Providers
- 2.4.2.5. Ethics And Integrity
- 2.4.2.5.1. Research Ethics
- 2.4.2.5.2. Data Integrity
- 2.4.3. Analytical Tools And Databases
- 2.5. Robust Quality Control
- 3. Market Dynamics
- 3.1. Chapter Overview
- 3.2. Forecast Methodology
- 3.2.1. Top-down Approach
- 3.2.2. Bottom-up Approach
- 3.2.3. Hybrid Approach
- 3.3. Market Assessment Framework
- 3.3.1. Total Addressable Market (Tam)
- 3.3.2. Serviceable Addressable Market (Sam)
- 3.3.3. Serviceable Obtainable Market (Som)
- 3.3.4. Currently Acquired Market (Cam)
- 3.4. Forecasting Tools And Techniques
- 3.4.1. Qualitative Forecasting
- 3.4.2. Correlation
- 3.4.3. Regression
- 3.4.4. Extrapolation
- 3.4.5. Convergence
- 3.4.6. Sensitivity Analysis
- 3.4.7. Scenario Planning
- 3.4.8. Data Visualization
- 3.4.9. Time Series Analysis
- 3.4.10. Forecast Error Analysis
- 3.5. Key Considerations
- 3.5.1. Demographics
- 3.5.2. Government Regulations
- 3.5.3. Reimbursement Scenarios
- 3.5.4. Market Access
- 3.5.5. Supply Chain
- 3.5.6. Industry Consolidation
- 3.5.7. Pandemic / Unforeseen Disruptions Impact
- 3.6. Limitations
- 4. Macro-economic Indicators
- 4.1. Chapter Overview
- 4.2. Market Dynamics
- 4.2.1. Time Period
- 4.2.1.1. Historical Trends
- 4.2.1.2. Current And Forecasted Estimates
- 4.2.2. Currency Coverage
- 4.2.2.1. Major Currencies Affecting The Market
- 4.2.2.2. Factors Affecting Currency Fluctuations On The Industry
- 4.2.2.3. Impact Of Currency Fluctuations On The Industry
- 4.2.3. Foreign Currency Exchange Rate
- 4.2.3.1. Impact Of Foreign Exchange Rate Volatility On The Market
- 4.2.3.2. Strategies For Mitigating Foreign Exchange Risk
- 4.2.4. Recession
- 4.2.4.1. Assessment Of Current Economic Conditions And Potential Impact On The Market
- 4.2.4.2. Historical Analysis Of Past Recessions And Lessons Learnt
- 4.2.5. Inflation
- 4.2.5.1. Measurement And Analysis Of Inflationary Pressures In The Economy
- 4.2.5.2. Potential Impact Of Inflation On The Market Evolution
- 4.2.6. Interest Rates
- 4.2.6.1. Interest Rates And Their Impact On The Market
- 4.2.6.2. Strategies For Managing Interest Rate Risk
- 4.2.7. Commodity Flow Analysis
- 4.2.7.1. Type Of Commodity
- 4.2.7.2. Origins And Destinations
- 4.2.7.3. Values And Weights
- 4.2.7.4. Modes Of Transportation
- 4.2.8. Global Trade Dynamics
- 4.2.8.1. Import Scenario
- 4.2.8.2. Export Scenario
- 4.2.8.3. Trade Policies
- 4.2.8.4. Strategies For Mitigating The Risks Associated With Trade Barriers
- 4.2.8.5. Impact Of Trade Barriers On The Market
- 4.2.9. War Impact Analysis
- 4.2.9.1. Russian-ukraine War
- 4.2.9.2. Israel-hamas War
- 4.2.10. Covid Impact / Related Factors
- 4.2.10.1. Global Economic Impact
- 4.2.10.2. Industry-specific Impact
- 4.2.10.3. Government Response And Stimulus Measures
- 4.2.10.4. Future Outlook And Adaptation Strategies
- 4.2.11. Other Indicators
- 4.2.11.1. Fiscal Policy
- 4.2.11.2. Consumer Spending
- 4.2.11.3. Gross Domestic Product
- 4.2.11.4. Employment
- 4.2.11.5. Taxes
- 4.2.11.6. Stock Market Performance
- 4.2.11.7. Cross Border Dynamics
- 4.3. Conclusion
- Section Ii: Qualitative Insights
- 5. Executive Summary
- 6. Introduction
- 6.1. Chapter Overview
- 6.2. Structure Of Antibodies
- 6.3. History Of Antibody Discovery
- 6.4. Antibody Isotypes
- 6.5. Mechanism Of Action Of Antibodies
- 6.6. Classification Of Antibodies
- 6.6.1. Monoclonal Antibodies
- 6.6.2. Polyclonal Antibodies
- 6.6.3. Bispecific Antibodies
- 6.7. Applications Of Antibodies
- 6.8. Concluding Remarks
- 7. Antibody Discovery: Processes And Methods
- 7.1. Chapter Overview
- 7.2. Antibody Discovery Process
- 7.2.1. Target Selection And Validation
- 7.2.2. Hit Generation
- 7.2.3. Lead Selection
- 7.2.4. Lead Optimization
- 7.2.4.1. Humanization
- 7.2.4.2. Affinity Maturation
- 7.2.4.3. Fc Engineering
- 7.2.5. Lead Characterization
- 7.2.6. Candidate Selection
- 7.3. Antibody Discovery Methods
- 7.3.1. Hybridoma Method
- 7.3.2. In Vitro Display Method
- 7.3.2.1. Phage Display Method
- 7.3.2.2. Yeast Display Method
- 7.3.2.3. Ribosomal Display Method
- 7.3.3. Transgenic Animal-based Method
- 7.3.4. Single B Cell Based Method
- 7.4. Advantages And Disadvantages Of Existing Antibody Discovery Methods
- 7.5. Evolution Of Monoclonal Antibodies
- 7.5.1. Fully Human Monoclonal Antibodies
- 7.6. Concluding Remarks
- Section Iii: Competitive landscape
- 8. Market Landscape: Antibody Discovery Service Providers
- 8.1. Chapter Overview
- 8.2. Antibody Discovery Service Providers: Market Landscape
- 8.2.1. Analysis By Year Of Establishment
- 8.2.2. Analysis By Company Size
- 8.2.3. Analysis By Location Of Headquarters
- 8.2.4. Analysis By Type Of Antibody Discovery Service Offered
- 8.2.5. Analysis By Type Of Antibody Discovery Supported
- 8.2.6. Analysis By Type Of Antibody Discovery Method
- 8.2.7. Analysis By Animal Model Used
- 8.2.8. Analysis By Type Of Antibody Discovery Method And Type Of Antibody Discovery Supported
- 8.2.9. Analysis By Type Of Antibody Discovery Service Offered And Location Of Headquarters
- 8.2.10. Analysis By Application Area
- 9. Market Landscape: Antibody Discovery Technologies / Platforms
- 9.1. Chapter Overview
- 9.2. Antibody Discovery Technologies / Platforms: Market Landscape
- 9.2.1. Analysis By Type Of Antibody Discovery Method Used
- 9.2.2. Analysis By Type Of Antibody Discovery Supported
- 9.2.3. Analysis By Animal Model Used
- 9.2.4. Analysis By Type Of Antibody Discovery Method Used And Type Of Antibody Discovery Supported
- 9.2.5. Analysis By Type Of Antibody Discovery Method And Location Of Headquarters Of Technology / Platform Providers
- 9.3. Antibody Discovery Technology / Platform Providers Landscape
- 9.3.1. Analysis By Year Of Establishment
- 9.3.2. Analysis By Company Size
- 9.3.3. Analysis By Location Of Headquarters
- 9.3.4. Most Active Players: Analysis By Number Of Technologies
- 10. Company Competitiveness Analysis
- 10.1. Chapter Overview
- 10.2. Assumptions And Key Parameters
- 10.3. Methodology
- 10.4. Overview Of Peer Groups
- 10.5. Company Competitiveness Analysis
- 10.5.1. Antibody Discovery Service Providers Headquartered In North America
- 10.5.2. Antibody Discovery Service Providers Headquartered In Europe
- 10.5.3. Antibody Discovery Service Providers Headquartered In Asia-pacific
- 11. Technology Competitiveness Analysis
- 11.1. Chapter Overview
- 11.2. Assumptions And Key Parameters
- 11.3. Methodology
- 11.4. Overview Of Peer Groups
- 11.5. Technology Competitiveness Analysis
- 11.5.1. Antibody Discovery Technologies / Platforms Provided By Players Headquartered In North America
- 11.5.2. Antibody Discovery Technologies / Platforms Provided By Players Headquartered In Europe
- 11.5.3. Antibody Discovery Technologies / Platforms Provided By Players Headquartered In Asia-pacific
- Section Iv: Company Profiles
- 12. Antibody Discovery Service Providers: Company Profiles Of Players Based In North America
- 12.1. Chapter Overview
- 12.2. Abwiz Bio
- 12.2.1. Company Overview
- 12.2.2. Antibody Discovery Service Portfolio
- 12.2.3. Recent Developments And Future Outlook
- 12.3. Abzena
- 12.3.1. Company Overview
- 12.3.2. Antibody Discovery Service Portfolio
- 12.3.3. Recent Developments And Future Outlook
- 12.4. Creative Biolabs
- 12.4.1. Company Overview
- 12.4.2. Antibody Discovery Service Portfolio
- 12.4.3. Recent Developments And Future Outlook
- 12.5. Detaibio
- 12.5.1. Company Overview
- 12.5.2. Antibody Discovery Service Portfolio
- 12.5.3. Recent Developments And Future Outlook
- 12.6. Immunoprecise Antibodies
- 12.6.1. Company Overview
- 12.6.2. Financial Information
- 12.6.3. Antibody Discovery Service Portfolio
- 12.6.4. Recent Developments And Future Outlook
- 12.7. Integral Molecular
- 12.7.1. Company Overview
- 12.7.2. Antibody Discovery Service Portfolio
- 12.7.3. Recent Developments And Future Outlook
- 12.8. Syd Labs
- 12.8.1. Company Overview
- 12.8.2. Antibody Discovery Service Portfolio
- 12.8.3. Recent Developments And Future Outlook
- 13. Antibody Discovery Service Providers: Company Profiles Of Players Based In Europe
- 13.1. Chapter Overview
- 13.2. Biotem
- 13.2.1. Company Overview
- 13.2.2. Antibody Discovery Service Portfolio
- 13.2.3. Recent Developments And Future Outlook
- 13.3. Fairjourney Biologics
- 13.3.1. Company Overview
- 13.3.2. Antibody Discovery Service Portfolio
- 13.3.3. Recent Developments And Future Outlook
- 13.4. Fusion Antibodies
- 13.4.1. Company Overview
- 13.4.2. Financial Information
- 13.4.3. Antibody Discovery Service Portfolio
- 13.4.4. Recent Developments And Future Outlook
- 13.5. Proteogenix
- 13.5.1. Company Overview
- 13.5.2. Antibody Discovery Service Portfolio
- 13.5.3. Recent Developments And Future Outlook
- 14. Antibody Discovery Service Providers: Company Profiles Of Players Based In Asia-pacific
- 14.1. Chapter Overview
- 14.2. Aragen Life Sciences
- 14.2.1. Company Overview
- 14.2.2. Antibody Discovery Service Portfolio
- 14.2.3. Recent Developments And Future Outlook
- 14.3. Chempartner
- 14.3.1. Company Overview
- 14.3.2. Antibody Discovery Service Portfolio
- 14.3.3. Recent Developments And Future Outlook
- 14.4. Viva Biotech
- 14.4.1. Company Overview
- 14.4.2. Financial Information
- 14.4.3. Antibody Discovery Service Portfolio
- 14.4.4. Recent Developments And Future Outlook
- 14.5. Wuxi Biologics
- 14.5.1. Company Overview
- 14.5.2. Financial Information
- 14.5.3. Antibody Discovery Service Portfolio
- 14.5.4. Recent Developments And Future Outlook
- 15. Antibody Discovery Technology / Platform Providers: Company Profiles Of Players Based In North America
- 15.1. Chapter Overview
- 15.2. Ablexis
- 15.2.1. Company Overview
- 15.2.2. Antibody Discovery Technology / Platform Portfolio
- 15.2.3. Recent Developments And Future Outlook
- 15.3. Harbour Biomed
- 15.3.1. Company Overview
- 15.3.2. Antibody Discovery Technology / Platform Portfolio
- 15.3.3. Financial Information
- 15.3.4. Recent Developments And Future Outlook
- 15.4. Immunome
- 15.4.1. Company Overview
- 15.4.2. Antibody Discovery Technology / Platform Portfolio
- 15.4.3. Recent Developments And Future Outlook
- 16. Antibody Discovery Technology / Platform Providers: Company Profiles Of Players Based In Europe
- 16.1. Chapter Overview
- 16.2. Genmab
- 16.2.1. Company Overview
- 16.2.2. Antibody Discovery Technology / Platform Portfolio
- 16.2.3. Financial Information
- 16.2.4. Recent Developments And Future Outlook
- 16.3. Isogenica
- 16.3.1. Company Overview
- 16.3.2. Antibody Discovery Technology / Platform Portfolio
- 16.3.3. Recent Developments And Future Outlook
- Section V: Market Trends
- 17. Partnerships And Collaborations
- 17.1. Chapter Overview
- 17.2. Partnership Models
- 17.3. Antibody Discovery Services And Platforms: Partnerships And Collaborations
- 17.3.1. Analysis By Year Of Partnership
- 17.3.2. Analysis By Type Of Partnership
- 17.3.3. Analysis By Year And Type Of Partnership
- 17.3.4. Analysis By Type Of Antibody
- 17.3.5. Key Technologies: Analysis By Number Of Partnerships
- 17.3.6. Most Active Players: Analysis By Number Of Partnerships
- 17.3.7. Analysis By Geography
- 17.3.7.1. Local And International Agreements
- 17.3.7.2. Intracontinental And Intercontinental Agreements
- 18. Funding And Investment Analysis
- 18.1. Chapter Overview
- 18.2. Types Of Funding
- 18.3. Antibody Discovery Service And Platform Providers: Funding And Investment Analysis
- 18.3.1. Analysis By Year Of Funding
- 18.3.1.1. Cumulative Year-wise Trend Of Funding Instances
- 18.3.1.2. Cumulative Year-wise Trend Of Amount Invested
- 18.3.2. Analysis By Type Of Funding
- 18.3.2.1. Analysis By Funding Instances
- 18.3.2.2. Analysis By Amount Invested
- 18.3.3. Analysis By Year And Type Of Funding
- 18.3.4. Analysis By Number Of Funding Instances And Type Of Players
- 18.3.5. Analysis By Type Of Player Amount Invested
- 18.3.6. Analysis By Geography
- 18.3.7. Most Active Players: Analysis By Number Of Funding Instances
- 18.3.8. Most Active Players: Analysis By Amount Invested
- 18.3.9. Leading Investors: Analysis By Number Of Funding Instances
- 18.4. Summary Of Investments
- Section Vi: Market Opportunity Analysis
- 19. Market Impact Analysis: Drivers, Restraints, Opportunities And Challenges
- 19.1. Chapter Overview
- 19.2. Market Drivers
- 19.3. Market Restraints
- 19.4. Market Opportunities
- 19.5. Market Challenges
- 19.6. Conclusion
- 20. Global Antibody Discovery Services Market
- 20.1. Chapter Overview
- 20.2. Assumptions And Methodology
- 20.3. Antibody Discovery Services Market, Historical Trends (Since 2020) And Forecasted Estimates (Till 2035)
- 20.3.1. Scenario Analysis
- 20.3.1.1. Conservative Scenario
- 20.3.1.2. Optimistic Scenario
- 20.4. Key Market Segmentations
- 21. Antibody Discovery Services Market, By Antibody Discovery Step
- 21.1. Chapter Overview
- 21.2. Key Assumptions And Methodology
- 21.3. Antibody Discovery Services Market: Distribution By Antibody Discovery Step
- 21.3.1. Antibody Discovery Services Market For Hit Generation, Historical Trends (Since 2020) And Forecasted Estimates (Till 2035)
- 21.3.2. Antibody Discovery Services Market For Lead Selection, Historical Trends (Since 2020) And Forecasted Estimates (Till 2035)
- 21.3.3. Antibody Discovery Services Market For Lead Optimization, Historical Trends (Since 2020) And Forecasted Estimates (Till 2035)
- 21.4. Data Triangulation And Validation
- 22. Antibody Discovery Services Market, By Type Of Antibody Discovery Method
- 22.1. Chapter Overview
- 22.2. Key Assumptions And Methodology
- 22.3. Antibody Discovery Services Market: Distribution By Type Of Antibody Discovery Method
- 22.3.1. Antibody Discovery Services Market For Hybridoma-based Methods, Historical Trends (Since 2020) And Forecasted Estimates (Till 2035)
- 22.3.2. Antibody Discovery Services Market For Phage Display Library-based Methods, Historical Trends (Since 2020) And Forecasted Estimates (Till 2035)
- 22.3.3. Antibody Discovery Services Market For Transgenic Animal-based Methods, Historical Trends (Since 2020) And Forecasted Estimates (Till 2035)
- 22.3.4. Antibody Discovery Services Market For Yeast Display-based Methods, Historical Trends (Since 2020) And Forecasted Estimate, (Till 2035)
- 22.3.5. Antibody Discovery Services Market For Single Cell-based Methods, Historical Trends (Since 2020) And Forecasted Estimates (Till 2035)
- 22.3.6. Antibody Discovery Services Market For Other Methods, Historical Trends (Since 2020) And Forecasted Estimates (Till 2035)
- 22.4. Data Triangulation And Validation
- 23. Antibody Discovery Services Market, By Nature Of Antibody
- 23.1. Chapter Overview
- 23.2. Key Assumptions And Methodology
- 23.3. Antibody Discovery Services Market: Distribution By Nature Of Antibody
- 23.3.1. Antibody Discovery Services Market For Human Antibodies, Historical Trends (Since 2020) And Forecasted Estimates (Till 2035)
- 23.3.2. Antibody Discovery Services Market For Humanized Antibodies, Historical Trends (Since 2020) And Forecasted Estimates (Till 2035)
- 23.3.3. Antibody Discovery Services Market For Chimeric Antibodies, Historical Trends (Since 2020) And Forecasted Estimates (Till 2035)
- 23.3.4. Antibody Discovery Services Market For Murine Antibodies, Historical Trends (Since 2020) And Forecasted Estimates (Till 2035)
- 23.4. Data Triangulation And Validation
- 24. Antibody Discovery Services Market, By Therapeutic Area
- 24.1. Chapter Overview
- 24.2. Key Assumptions And Methodology
- 24.3. Antibody Discovery Services Market: Distribution By Therapeutic Area
- 24.3.1. Antibody Discovery Services Market For Oncological Disorders, Historical Trends (Since 2020) And Forecasted Estimates (Till 2035)
- 24.3.2. Antibody Discovery Services Market For Immunological Disorders, Historical Trends (Since 2020) And Forecasted Estimates (Till 2035)
- 24.3.3. Antibody Discovery Services Market For Infectious Diseases, Historical Trends (Since 2020) And Forecasted Estimates (Till 2035)
- 24.3.4. Antibody Discovery Services Market For Cardiovascular Disorders, Historical Trends (Since 2020) And Forecasted Estimates (Till 2035)
- 24.3.5. Antibody Discovery Services Market For Neurological Disorders, Historical Trends (Since 2020) And Forecasted Estimates (Till 2035)
- 24.3.6. Antibody Discovery Services Market For Other Disorders, Historical Trends (Since 2020) And Forecasted Estimates (Till 2035)
- 24.4. Data Triangulation And Validation
- 25. Antibody Discovery Services Market, By Type Of Antibody
- 25.1. Chapter Overview
- 25.2. Key Assumptions And Methodology
- 25.3. Antibody Discovery Services Market: Distribution By Type Of Antibody
- 25.3.1. Antibody Discovery Services Market For Monoclonal Antibodies, Historical Trends (Since 2020) And Forecasted Estimates (Till 2035)
- 25.3.2. Antibody Discovery Services Market For Bispecific Antibodies, Historical Trends (Since 2020) And Forecasted Estimates (Till 2035)
- 25.3.3. Antibody Discovery Services Market For Immunoconjugates, Historical Trends (Since 2020) And Forecasted Estimates (Till 2035)
- 25.4. Data Triangulation And Validation
- 26. Antibody Discovery Services Market, By Geographical Regions
- 26.1. Chapter Overview
- 26.2. Key Assumptions And Methodology
- 26.3. Antibody Discovery Services Market: Distribution By Geographical Regions
- 26.3.1. Antibody Discovery Services Market In North America, Historical Trends (Since 2020) And Forecasted Estimates (Till 2035)
- 26.3.1.1. Antibody Discovery Services Market In The Us, Historical Trends (Since 2020) And Forecasted Estimates (Till 2035)
- 26.3.1.2. Antibody Discovery Services Market In Canada, Historical Trends (Since 2020) And Forecasted Estimates (Till 2035)
- 26.3.2. Antibody Discovery Services Market In Europe, Historical Trends (Since 2020) And Forecasted Estimates (Till 2035)
- 26.3.2.1. Antibody Discovery Services Market In Germany, Historical Trends (Since 2020) And Forecasted Estimates (Till 2035)
- 26.3.2.2. Antibody Discovery Services Market In The Uk, Historical Trends (Since 2020) And Forecasted Estimates (Till 2035)
- 26.3.2.3. Antibody Discovery Services Market In France, Historical Trends (Since 2020) And Forecasted Estimates (Till 2035)
- 26.3.2.4. Antibody Discovery Services Market In Italy, Historical Trends (Since 2020) And Forecasted Estimates (Till 2035)
- 26.3.2.5. Antibody Discovery Services Market In Spain, Historical Trends (Since 2020) And Forecasted Estimates (Till 2035)
- 26.3.2.6. Antibody Discovery Services Market In Rest Of Europe, Historical Trends (Since 2020) And Forecasted Estimates (Till 2035)
- 26.3.3. Antibody Discovery Services Market In Asia-pacific, Historical Trends (Since 2020) And Forecasted Estimates (Till 2035)
- 26.3.3.1. Antibody Discovery Services Market In China, Historical Trends (Since 2020) And Forecasted Estimates (Till 2035)
- 26.3.3.2. Antibody Discovery Services Market In Japan, Historical Trends (Since 2020) And Forecasted Estimates (Till 2035)
- 26.3.3.3. Antibody Discovery Services Market In India, Historical Trends (Since 2020) And Forecasted Estimates (Till 2035)
- 26.3.3.4. Antibody Discovery Services Market In South Korea, Historical Trends (Since 2020) And Forecasted Estimates (Till 2035)
- 26.3.3.5. Antibody Discovery Services Market In Australia, Historical Trends (Since 2020) And Forecasted Estimates (Till 2035)
- 26.3.4. Antibody Discovery Services Market In Middle East And North Africa, Historical Trends (Since 2020) And Forecasted Estimates (Till 2035)
- 26.3.4.1. Antibody Discovery Services Market In Egypt, Historical Trends (Since 2020) And Forecasted Estimates (Till 2035)
- 26.3.4.2. Antibody Discovery Services Market In Israel, Historical Trends (Since 2020) And Forecasted Estimates (Till 2035)
- 26.3.4.3. Antibody Discovery Services Market In Saudi Arabia, Historical Trends (Since 2020) And Forecasted Estimates (Till 2035)
- 26.3.4.4. Antibody Discovery Services Market In Rest Of Middle East And North Africa, Historical Trends (Since 2020) And Forecasted Estimates (Till 2035)
- 26.3.5. Antibody Discovery Services Market In Latin America, Historical Trends (Since 2020) And Forecasted Estimates (Till 2035)
- 26.3.5.1. Antibody Discovery Services Market In Brazil, Historical Trends (Since 2020) And Forecasted Estimates (Till 2035)
- 26.3.5.2. Antibody Discovery Services Market In Argentina, Historical Trends (Since 2020) And Forecasted Estimates (Till 2035)
- 26.3.5.3. Antibody Discovery Services Market In Mexico, Historical Trends (Since 2020) And Forecasted Estimates (Till 2035)
- 26.3.5.4. Antibody Discovery Services Market In Rest Of Latin America, Historical Trends (Since 2020) And Forecasted Estimates (Till 2035)
- 26.4. Antibody Discovery Services Market, By Geographical Regions: Market Dynamics Assessment
- 26.4.1. Penetration Growth (P-g) Matrix
- 26.4.2. Market Movement Analysis
- 26.5. Data Triangulation And Validation
- 27. Global Antibody Discovery Technologies / Platforms Market
- 27.1. Chapter Overview
- 27.2. Assumptions And Methodology
- 27.3. Antibody Discovery Technologies / Platforms Market: Forecasted Estimates, Till 2035
- 27.3.1. Scenario Analysis
- 27.3.1.1. Conservative Scenario
- 27.3.1.2. Optimistic Scenario
- 27.4. Key Market Segmentations
- 28. Antibody Discovery Technologies / Platforms Market, By Type Of Antibody
- 28.1. Chapter Overview
- 28.2. Key Assumptions And Methodology
- 28.3. Antibody Discovery Technologies / Platforms Market: Distribution By Type Of Antibody
- 28.3.1. Antibody Discovery Technologies / Platforms Market For Monoclonal Antibodies, Forecasted Estimates (Till 2035)
- 28.3.2. Antibody Discovery Technologies / Platforms Market For Bispecific Antibodies, Forecasted Estimates (Till 2035)
- 28.3.3. Antibody Discovery Technologies / Platforms Market For Antibody Drug Conjugates, Forecasted Estimates (Till 2035)
- 28.3.4. Antibody Discovery Technologies / Platforms Market For Other Antibodies, Forecasted Estimates (Till 2035)
- 28.4. Data Triangulation And Validation
- 29. Antibody Discovery Technologies / Platforms Market, By Type Of End-user
- 29.1. Chapter Overview
- 29.2. Key Assumptions And Methodology
- 29.3. Antibody Discovery Technologies / Platforms Market: Distribution By Type Of End-user
- 29.3.1. Antibody Discovery Technologies / Platforms Market For In-house, Forecasted Estimates (Till 2035)
- 29.3.2. Antibody Discovery Technologies / Platforms Market For Contract Research Organizations, Forecasted Estimates (Till 2035)
- 29.4. Data Triangulation And Validation
- 30. Antibody Discovery Technologies / Platforms Market, By Geographical Regions
- 30.1. Chapter Overview
- 30.2. Key Assumptions And Methodology
- 30.3. Antibody Discovery Technologies / Platforms: Distribution By Geographical Regions
- 30.3.1. Antibody Discovery Technologies / Platforms Market In North America, Forecasted Estimates (Till 2035)
- 30.3.1.1. Antibody Discovery Technologies / Platforms Market In The Us, Forecasted Estimates (Till 2035)
- 30.3.1.2. Antibody Discovery Technologies / Platforms Market In Canada, Forecasted Estimates (Till 2035)
- 30.3.2. Antibody Discovery Technologies / Platforms Market In Europe, Forecasted Estimates (Till 2035)
- 30.3.2.1. Antibody Discovery Technologies / Platforms Market In Switzerland, Forecasted Estimates (Till 2035)
- 30.3.2.2. Antibody Discovery Technologies / Platforms Market In Germany, Forecasted Estimates (Till 2035)
- 30.3.2.3. Antibody Discovery Technologies / Platforms Market In The Uk, Forecasted Estimates (Till 2035)
- 30.3.2.4. Antibody Discovery Technologies / Platforms Market In France, Forecasted Estimates (Till 2035)
- 30.3.2.5. Antibody Discovery Technologies / Platforms Market In Rest Of Europe, Forecasted Estimates (Till 2035)
- 30.3.3. Antibody Discovery Technologies / Platforms Market In Asia-pacific, Forecasted Estimates (Till 2035)
- 30.3.3.1. Antibody Discovery Technologies / Platforms Market In China, Forecasted Estimates (Till 2035)
- 30.3.3.2. Antibody Discovery Technologies / Platforms Market In Singapore, Forecasted Estimates (Till 2035)
- 30.3.3.3. Antibody Discovery Technologies / Platforms Market In Japan, Forecasted Estimates (Till 2035)
- 30.3.3.4. Antibody Discovery Technologies / Platforms Market In South Korea, Forecasted Estimates (Till 2035)
- 30.4. Market Dynamics Assessment
- 30.4.1. Penetration Growth (P-g) Matrix
- 30.5. Data Triangulation And Validation
- 31. Licensing Deal Structure
- 31.1. Chapter Overview
- 31.2. Key Parameters
- 31.3. Assumptions And Methodology
- 31.3.1. Overall Cash Flow For Licensee Companies
- 31.3.1.1. Total Expenses Incurred By A Licensee
- 31.3.1.2. Revenues Generated By A Licensee
- 31.3.2. Overall Cash Flow For Licensor
- 31.3.2.1. Total Expenses Incurred By The Licensor
- 31.3.2.2. Revenues By The Licensor
- 31.4. Key Analytical Outputs
- 31.4.1. Scenario 1: Variation Of Upfront Payments And Milestone Payments
- 31.4.2. Scenario 2: Variation Of Upfront Payments And Sales Based Royalties
- 31.4.3. Scenario 1: Variation Of Milestone Payments And Sales Based Royalties
- 32. Case In Point: Drug Discovery Processes Of Top Selling Antibodies
- 32.1. Chapter Overview
- 32.2. Humira (Adalimumab)
- 32.2.1. Drug Overview
- 32.2.2. Discovery Process And Method
- 32.2.3. Historical Sales
- 32.3. Keytruda (Pembrolizumab)
- 32.3.1. Drug Overview
- 32.3.2. Discovery Process And Method
- 32.3.3. Historical Sales
- 32.4. Stelara (Ustekinumab)
- 32.4.1. Drug Overview
- 32.4.2. Discovery Process And Method
- 32.4.3. Historical Sales
- 32.5. Opdivo (Nivolumab)
- 32.5.1. Drug Overview
- 32.5.2. Discovery Process And Method
- 32.5.3. Historical Sales
- 32.6. Darzalex (Daratumumab)
- 32.6.1. Drug Overview
- 32.6.2. Discovery Process And Method
- 32.6.3. Historical Sales
- 33. Future Growth Opportunities In Antibody Discovery
- 33.1. Chapter Overview
- 33.2. Upcoming Trends In Drug Discovery
- 33.3. Anticipated Shift From Monoclonal Antibodies To Other Novel Antibody Formats
- 33.3.1. Technological Advancements To Overhaul Conventional Antibody Discovery Processes
- 33.3.2. Transition To Cadd-based Approaches To Help Achieve Better Operational Efficiencies
- 33.3.3. Rising Demand For Antibody-based Treatment Options For Non-oncological Indications
- 33.4. Future Growth Opportunities In Emerging Economies
- 33.5. Concluding Remarks
- Section Vii: Other Exclusive Insights
- 34. Concluding Insights
- 35. Executive Insights
- Section Viii: Appendices
- 36. Appendix I: Tabulated Data
- 37. Appendix Ii: List Of Companies And Organizations
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
